| Literature DB >> 33662381 |
Kazuhiko Matsuo1, Kosuke Kitahata1, Yuichiro Kaibori2, Yuka Arima1, Arisa Iwama1, Mana Ito1, Yuta Hara3, Daisuke Nagakubo2, Ying-Shu Quan4, Fumio Kamiyama4, Naoki Oiso5, Akira Kawada5, Osamu Yoshie6, Takashi Nakayama7.
Abstract
Psoriasis is a chronic skin disease associated with T helper (Th)17-mediated inflammation. Because CCR4 is a major chemokine receptor expressed on Th17 cells, we investigated the role of CCR4 in a modified imiquimod-induced psoriasis model that showed enhanced skin infiltration of Th17 cells. CCR4-deficient mice had less severe skin disease than wild-type mice. Th17 cells were decreased in the skin lesions and regional lymph nodes of CCR4-deficient mice. In the regional lymph nodes of wild-type mice, CD44+ memory Th17 cells expressing CCR4 were found to be clustered with dendritic cells expressing CCL22, a ligand for CCR4. Such dendritic cell‒Th17 cell clusters were significantly decreased in CCR4-deficient mice. Similar results were obtained using the IL-23‒induced psoriasis model. In vitro, compound 22, a CCR4 antagonist, significantly reduced the expansion of Th17 cells in the coculture of CD11c+ dendritic cells and CD4+ T cells separately prepared from the regional lymph nodes of wild-type mice with psoriasis. In vivo, compound 22 ameliorated the psoriasis-like skin disease in wild-type mice with significant decreases of Th17 cells in the regional lymph nodes and skin lesions. Collectively, CCR4 is likely to play a role in the pathogenesis of psoriasis through the expansion of Th17 cells.Entities:
Year: 2021 PMID: 33662381 DOI: 10.1016/j.jid.2020.12.034
Source DB: PubMed Journal: J Invest Dermatol ISSN: 0022-202X Impact factor: 8.551